Interview 11 Jul 2017 The Advantage for the First Mover in NASH is Limited, says Genfit …enough,” said Hum. “As we see in other metabolic diseases, there’s a small number of patients in other metabolic diseases who are able to maintain that lifestyle.” “The point is… July 11, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Startup Scout 11 May 2018 This Oxford Biotech is Using DNA to Find New Peptide Drugs …variety of indications, from oncology and autoimmune diseases to metabolic, cardiovascular and infectious diseases seems exciting. However, there are not many peptide drugs on the market. It will be interesting… May 11, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Best in Biotech 6 Jun 2024 Eight biotech companies advancing the field of siRNA …thereby preventing them from being translated into proteins. This specific mechanism has the potential to treat a wide range of diseases, from genetic disorders and cancers to viral infections. Unlike… June 6, 2024 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 14 Apr 2025 Metabolomics: The study of biology’s dark matter …confined to a set of monomers, instead, they can be any small molecule resulting from metabolic reactions. “If genomics, transcriptomics, and proteomics are Lego kits, with metabolites you are now… April 14, 2025 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 17 Sep 2024 Estonia: Seven biotech companies to reckon with …potential of N6-methyladenosine (m6A), a chemical modification found in RNA that is implicated in various neurodegenerative and neuropsychiatric diseases, as well as cancer. Chemestmed’s work in epitranscriptomics aims to regulate… September 17, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2023 Cambrian Bio to boost aging pipeline with Amplifier Therapeutics launch …AMPK decreases as we age. Given the central role of AMPK in whole body energy regulation, AMPK activators have broad potential therapeutic applications in metabolic conditions, cardiovascular diseases, kidney diseases,… March 15, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Jnana Therapeutics raises $107M for PKU program and announces new Roche partnership Jnana Therapeutics has entered into a second collaboration and license agreement with Roche for the discovery of small molecule drugs for the treatment of cancer, immune-mediated and neurological diseases. The… November 15, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 May 2025 Interleukin therapeutics: 9 companies to follow in 2025 …interleukin as treatments for cancer, autoimmune conditions, and inflammatory diseases. But while some interleukin-based drugs have reached the market, many early attempts were held back by toxicity and a lack… May 27, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 13 May 2025 Nine biotech companies in Montreal to keep an eye on in 2025 …multispecific antibodies for cancer and autoimmune diseases. It has four candidates – Leap 1009 and Leap 1030 for autoimmune diseases, and Leap 1121 and an undisclosed candidate to treat cancer,… May 13, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 6 Mar 2025 Top biotech deals of February 2025 …American biotechs Alumis and Acelyrin declared that the two would merge. They will now form a company solely focused on creating treatments for immune-mediated diseases. With a combined cash runway… March 6, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Feb 2019 10 European Genomics Companies to Watch Out For …diseases to those developing technologies for sequencing genomes more quickly, cheaply and accurately than ever before. Such is the size of the genomic datasets being generated, even finding a way… February 18, 2019 - 8 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Alexion, AstraZeneca Rare Disease to acquire genomic medicine company LogicBio Therapeutics …of genes to address genetic diseases, as well as a platform designed to improve viral vector manufacturing processes. These platforms, coupled with LogicBio’s highly experienced team and Alexion’s advancements with… October 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email